Takeda

This study compares a new version of the dengue vaccine to the current approved one in healthy adults aged 18 to 60 who have never had dengue. Participants receive two shots three months apart, and blood tests measure how well each vaccine triggers the immune system. The goal is …

This study tests the long-term safety of TAK-881, an immunoglobulin infusion, in adults and children with primary immunodeficiency diseases (PIDD). Participants, who must have completed a prior study, receive regular infusions every 2 to 4 weeks. The goal is to see if the treatme…

This study tests whether TAK-279 can improve symptoms of two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. About 18 adults will receive the drug for up to 52 weeks. The main goal is to see if their skin becomes clear or almost cle…

This study checks if the drug fazirsiran is safe and works over the long term for people with liver disease caused by Alpha-1 antitrypsin deficiency. About 31 adults who were in earlier studies get fazirsiran every 3 months. Researchers track side effects and check if the drug sl…

This study tests an oral drug called Mobocertinib in Japanese adults with non-small cell lung cancer. In the first part, different groups receive increasing doses to find the safest amount. In the second part, participants get that best dose to see if their tumors shrink. The goa…

This study observes 335 people with moderate to severe Crohn's disease who are taking Entyvio (vedolizumab) as part of their regular care. The goal is to see how safe and effective the drug is over the long term. Participants must have already tried other treatments without succe…

This program offers an unapproved drug, fruquintinib, to adults with metastatic colorectal cancer who have no other treatment options left. It is for compassionate use when standard therapies have failed and clinical trials are not possible. The goal is to provide access until th…

This study looks at 50 people in the UK with hereditary angioedema (HAE) who are starting or have started lanadelumab. Researchers will compare the number of swelling attacks in the year before starting the drug to up to two years after. Data comes from medical records, diaries, …

This study checks the long-term safety and side effects of the drug TAK-279 in adults with moderate-to-severe plaque psoriasis. About 1,950 participants will take the drug for up to 208 weeks, with regular clinic visits. The goal is to see how well people tolerate the treatment o…

This study tests a new daily pill (TAK-788) against standard chemotherapy in 354 adults with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). Participants are randomly assigned to receive either the pill or chemo. The main goal is to see …

This study monitors 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) for the first time. Researchers will track side effects and how well the drug controls swelling attacks over 12 months. The goal is to confirm the medicine's safety and …

This study tests an oral medication called TAK-279 in 207 adults with moderate to severe ulcerative colitis. Participants take either TAK-279 or a placebo for 12 weeks, then all receive TAK-279 for up to a year. The goal is to see if the drug reduces bowel inflammation and sympto…

This study is a follow-up for people with Hunter syndrome and cognitive problems who completed earlier studies. It aims to check the long-term safety of two medicines given together: idursulfase-IT (injected into the spine) and Elaprase (given through a vein). About 6 children an…

This study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy in 59 children and teens with advanced, newly diagnosed Hodgkin lymphoma. The goal was to find the safest dose and see how well the treatment shrinks tumors. Early results sugg…

This study monitors side effects and how well Revestive (teduglutide) controls symptoms in 250 people with short bowel syndrome. Participants receive injections under the skin as part of their regular care, and doctors watch for any problems over 36 months. The goal is to underst…

This study tests a medicine called TAK-771 in 26 Japanese adults with two rare nerve conditions, CIDP and MMN, which cause weakness and numbness. The goal is to see if the drug can prevent relapses and improve hand strength over up to 45 months of treatment. Participants receive …

This study looks at how well the drug brigatinib works in adults with a specific type of lung cancer (ALK-positive NSCLC). Researchers will track how long the cancer stays under control and how many patients respond to treatment. About 50 participants will receive brigatinib as p…

This study tests an experimental cell therapy called TAK-007 in adults with B-cell Non-Hodgkin Lymphoma that has come back or not responded to treatment. Participants first receive chemotherapy to lower certain white blood cells, then get one or three injections of TAK-007. The m…

This study tests two different targeted drugs, ponatinib and imatinib, given with low-intensity chemotherapy in adults newly diagnosed with a specific leukemia (Ph+ ALL). The goal is to see which drug leads to deeper remission with fewer cancer cells left. Participants take the d…

This study looks at the long-term safety of a medicine called TAK-755 for people with a rare inherited condition that causes dangerous blood clots and bleeding. Participants receive the drug regularly to prevent flare-ups or as needed to treat them. The goal is to see if long-ter…

This study aimed to see if a combination of immune-suppressing drugs could prevent the body from making antibodies that block the enzyme therapy ELAPRASE in boys with Hunter syndrome who had never been treated before. The plan was to give rituximab, methotrexate, and intravenous …

This study tests an experimental pill called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take the pill daily, sometimes with chemotherapy, and continue…

This study tests whether a new daily pill, zasocitinib, works better than an existing treatment, deucravacitinib, for adults with moderate-to-severe plaque psoriasis. About 606 participants will take one of the two treatments daily for 16 weeks. The main goal is to see if zasocit…

This study looks at how well the drug ixazomib works and what side effects it causes in adults with multiple myeloma who have already tried a different treatment. The goal is to see if switching to ixazomib can help control the disease longer. About 72 people are taking part in t…

This study follows 1,000 people with CD30-positive lymphoma who are already receiving or about to receive the drug brentuximab vedotin as part of their normal care. The main goal is to track any serious side effects that occur in real-world settings, not in a controlled trial. Re…

This study is a registry that collects information on the long-term safety and effectiveness of a medication called rhPTH(1-84) for people with chronic hypoparathyroidism. Participants receive their usual care from their doctors and fill out questionnaires during routine visits. …

This study is not testing a new treatment. Instead, it looks back at the medical records of over 1,000 adults in Brazil with ulcerative colitis or Crohn's disease who are taking or have taken vedolizumab. The goal is to see how long people stay on the drug and what other treatmen…

This study looks at genetic markers in tumor tissue to see if they can predict how well two different chemotherapy combinations work for people with advanced colorectal cancer. About 757 patients who have not had chemotherapy before will be randomly assigned to one of two treatme…

This study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to follow their infusion treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico to compare treatment adherence and side eff…

This study looks at how long Chinese patients with a specific type of advanced lung cancer (ALK-positive NSCLC) stay on the drug brigatinib when it's their first treatment. Researchers will also track how well the drug controls the cancer over time. The study does not give any ne…

This study looks at health records of pregnant women with constipation to see if taking the drug prucalopride is safe. Researchers will compare women who took prucalopride, those who took other constipation medicines, and those who took none. The goal is to find out if prucalopri…

This study looks at gene changes in tumor tissue from 787 people with advanced or recurrent colorectal cancer who took part in the earlier PARADIGM trial. Researchers want to see how these gene changes relate to how long patients lived or how long their cancer stayed under contro…

This study looks at how well a tool called CDPATH™ can predict the risk of serious complications in people with Crohn's disease within the next 3 years. About 200 adults with Crohn's will use the tool to learn their risk level (low, medium, or high) and discuss treatment options …